In recent weeks the U.S. Food and Drug Administration (FDA) has approved
sofosbuvir (Sovaldi) and simeprevir (Olysio) to treat chronic hepatitis C virus (HCV) infection. Sofosbuvir is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.
IDSA offers two email services to help members stay informed of new drug approvals and similar updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
IDSA members can sign up for these services online
. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network (HAN) messages and/or alerts from FDA, and provide your email address and name where indicated.)
For more information about the new hepatitis drugs and evolving clinical recommendations from IDSA and liver disease experts, see www.HCVGuidelines.org
Is Your Facility Experiencing Antibiotic Shortages?
Next Article >